Upon validation by ELISA quantification of five selected markers, we identified two novel markers, namely MCP-1 and prolactin, to be significantly elevated in sera of HCC patients who were eligible for potentially curative measures such as resection or liver transplant. This evidence concerns the gene CCL2 and hepatocellular carcinoma.